PD-L1 expression, microsatellite instability (MSI), and tumor mutation burden (TMB) are the most investigative biomarkers for predicting the response to immunotherapy (Patel and Kurzrock, 2015; Hugo et al., 2016; Goodman et al., 2017; Chang et al., 2018; Miao et al., 2018; Samstein et al., 2019). The gene discussed is CD274; the disease is neoplasm.